Mitralign Inc.

Mitralign plays in the hot markets of transcatheter mitral and tricuspid valve repair. Its Mitralign Percutaneous Annuloplasty System (MPAS) received the CE Mark this past February for treatment of functional mitral regurgitation, and its Trialign system for treatment of functional tricuspid regurgitation is now enrolling patients in an early feasibility IDE study in the United States. The $39.8 million the Tewksbury, MA-based company brought in in venture capital last quarter will be used to support clinical studies of Trialign and launch the MPAS system in Europe, according to the company. 

Continue >>

[image courtesy of the company]